O-015A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. (20th June 2018) - Chiritescu, G; Dumon, K; Mercadé, T Macarulla; Lang, I; Vivas, C Santos; Papai, Z; Janssens, J; Hendrickx, K; Pracht, M; Van den Eynde, M; Taïeb, J; Moons, V; et al.